K. Fishwick

Phase I study of temozolomide plus paclitaxel in patients with advanced malignant melanoma and associated in vitro investigations

A. Boddy, A. Maraveyas, A. Calvert, 2005, British Journal of Cancer.

Phase I clinical and pharmacokinetic study of pemetrexed and carboplatin in patients with malignant pleural mesothelioma.

A. Boddy, R. Plummer, H. Calvert, 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I study of pharmacologically based dosing of carboplatin with filgrastim support in women with epithelial ovarian cancer.

M. Millward, F. Chapman, A. Calvert, 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Pharmacological study of CT-2103 (XyotaxTM), a poly(L-glutamic acid)-paclitaxel conjugate administered every 3 weeks or every 2 weeks in a phase I study

J. Sludden, A. Boddy, D. Bisset, 2001 .

Topotecan in combination with carboplatin: phase I trial evaluation of two treatment schedules.

A. Schätzlein, J. Sludden, A. Boddy, 2002, Annals of oncology : official journal of the European Society for Medical Oncology.

Phase 1 pharmacokinetic (PK) study of CT-2103 given Q2 or Q3 weeks in patients with solid tumors

J. Sludden, A. Boddy, D. Bissett, 2003 .

Pharmacological study of paclitaxel duration of infusion combined with GFR-based carboplatin in the treatment of ovarian cancer

James G. Wright, J. Sludden, M. Highley, 2001, Cancer Chemotherapy and Pharmacology.

Phase I study of temozolomide plus paclitaxel in patients with advanced malignant melanoma and associated in vitro investigations

A. Calvert, C. Kelly, A. Azzabi, 2005, British Journal of Cancer.